glucagon has been researched along with semaglutide in 3 studies
Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (semaglutide) | Trials (semaglutide) | Recent Studies (post-2010) (semaglutide) |
---|---|---|---|---|---|
26,039 | 1,498 | 3,054 | 574 | 101 | 559 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Eckel, RH; Koh, KK; Lim, S | 1 |
Strey, C | 1 |
Coskun, T; DeVries, JH; Haupt, A; Heise, T; Li, J; Mari, A; Mather, KJ; Milicevic, Z; Pratt, EJ; Thomas, MK; Urva, S | 1 |
2 review(s) available for glucagon and semaglutide
Article | Year |
---|---|
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
[Technological Innovations in Diabetes Therapy].
Topics: Administration, Oral; Blood Glucose Self-Monitoring; Clinical Trials, Phase III as Topic; Diabetes Mellitus; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Insulin; Insulin Infusion Systems; Inventions; Pancreas, Artificial | 2018 |
1 trial(s) available for glucagon and semaglutide
Article | Year |
---|---|
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulins; Islets of Langerhans; Treatment Outcome | 2022 |